 Estrogen Receptor alpha
"Estrogen Receptor alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
| Descriptor ID |
D047628
|
| MeSH Number(s) |
D12.776.826.750.350.174
|
| Concept/Terms |
Estrogen Receptor alpha- Estrogen Receptor alpha
- Estradiol Receptor alpha
- Receptor alpha, Estradiol
- alpha, Estradiol Receptor
- Receptor alpha, Estrogen
- ERalpha
- Estrogen Receptors alpha
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor alpha".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor alpha".
This graph shows the total number of publications written about "Estrogen Receptor alpha" by people in this website by year, and whether "Estrogen Receptor alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 0 | 3 | | 2009 | 7 | 2 | 9 | | 2010 | 6 | 2 | 8 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 3 | 6 | | 2013 | 3 | 3 | 6 | | 2014 | 4 | 2 | 6 | | 2015 | 2 | 1 | 3 | | 2016 | 7 | 1 | 8 | | 2017 | 4 | 2 | 6 | | 2018 | 1 | 2 | 3 | | 2019 | 3 | 3 | 6 | | 2020 | 4 | 3 | 7 | | 2021 | 3 | 2 | 5 | | 2022 | 5 | 0 | 5 | | 2023 | 1 | 2 | 3 | | 2024 | 2 | 1 | 3 | | 2025 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Estrogen Receptor alpha" by people in Profiles.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Hamilton EP, Patel MR, Borges VF, Meisel JL, Okera M, Alemany CA, Pluard TJ, Wesolowski R, Sabanathan D, Miller KD, Conlin AK, McCarthy N, Shaw M, Tonda M, Shilkrut M, Lin NU. Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2-?advanced or metastatic breast cancer: phase 1/2 study results. Breast Cancer Res. 2025 Jul 01; 27(1):119.
-
Han AL, Vinod Paul K, Rao S, Brechbuhl HM, Sartorius CA, Ramachandran S, Kabos P. Estradiol (E2) concentration shapes the chromatin binding landscape of estrogen receptor alpha. J Biol Chem. 2025 Jul; 301(7):108499.
-
Gomes FP, Durbin KR, Schauer K, Nwachukwu JC, R Kobylski R, Njeri JW, Seath CP, Saviola AJ, McClatchy DB, Diedrich JK, Garrett PT, Papa AB, Ciolacu I, Kelleher NL, Nettles KW, Yates JR. Native top-down proteomics enables discovery in endocrine-resistant breast cancer. Nat Chem Biol. 2025 Aug; 21(8):1205-1213.
-
Liang J, Yao X, Aouad P, Wang BE, Crocker L, Chaudhuri S, Liang Y, Darmanis S, Giltnane J, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Hafner M, Metcalfe C. ERa dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nat Cancer. 2025 Feb; 6(2):357-371.
-
Hemphill WO, Steiner HR, Kominsky JR, Wuttke DS, Cech TR. Transcription factors ERa and Sox2 have differing multiphasic DNA- and RNA-binding mechanisms. RNA. 2024 07 16; 30(8):1089-1105.
-
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug; 35(8):707-717.
-
Severyn NT, Esparza P, Gao H, Mickler EA, Albrecht ME, Fisher AJ, Yakubov B, Cook TG, Slaven JE, Walts AD, Tepper RS, Lahm T. Effect of estrogen receptor a on cardiopulmonary adaptation to chronic developmental hypoxia in a rat model. Am J Physiol Lung Cell Mol Physiol. 2024 Jun 01; 326(6):L786-L795.
-
Wahdan-Alaswad RS, Edgerton SM, Kim HM, Tan AC, Haugen BR, Liu B, Thor AD. Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer. Cell Cycle. 2024 Apr; 23(7-8):747-766.
-
Li Z, Li T, Yates ME, Wu Y, Ferber A, Chen L, Brown DD, Carroll JS, Sikora MJ, Tseng GC, Oesterreich S, Lee AV. The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer. Cancer Res. 2023 08 15; 83(16):2656-2674.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|